Candidate for the third edition of the Eurasanté Bio-Accelerator international call for projects, the NIRAMAI company, based in India, has distinguished itself and joined the program to accelerate innovative health companies in Hauts-de-France. The winning company benefits from the « softlanding package » offered by Eurasanté, worth 5.000 euros, allowing it to st up in the Hauts-de-France area.
Launched in March 2021, the third edition of the Eurasanité Bio-Accelerator MedTech and e-health call for projects is open to foreign companies seeking to penetrate the European health market.
This third edition of the call for projects makes it possible to offer NIRAMAI, an Indian company whose mission is to creat a universal breast cancer screening method, a « soft-landing package » with a value of 5.000 euros to facilitate the creation of a subsidiary in France.
NIRAMAI is a startup developing new breast cancer screening software using artificial intelligence on thermographic images to enable a portable solution that is low cost, easy to use and requires minimal human supervision.
« We are very happy that Eurasante jury has given us an opportunity to be part of their acceleration program. Niramai has developed a radiation-free, privacy-conscious automated test for early detection of breast cancer. Eurasante provides us an excellent platform to collaborate with clinical experts and reputed hospitals in the northern France region and validate our Indian technology furthermore and save lives of many European women!»
The company benefits from Eurasanté’s expertise in innovation financing, business development, human resources management and market access to support its deployment in France. In particular, it has access to a network of key partners in the area to boost its development though the establishement of new collaborations, with institutional, clinical, industrial and scientific players.